New hope for Hard-to-Treat colorectal cancer: drug combo enters Mid-Stage trial
Disease control
Recruiting now
This Phase 2 trial is testing whether a new drug called TL938, taken as a pill, combined with the targeted therapy trastuzumab (given by IV), can shrink tumors in people with HER2-positive colorectal cancer that has spread or come back. The study will enroll 80 adults who have al…
Phase: PHASE2 • Sponsor: Suzhou Teligene Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC